126 related articles for article (PubMed ID: 37196550)
1. Determination of Bendamustine, Gemcitabine and Vinorelbine (BEGEV) regimen in spiked human plasma using multivariate model update chemometric methods.
Sharkawi MMZ; Mohamed NR; El-Saadi MT; Amin NH
Spectrochim Acta A Mol Biomol Spectrosc; 2023 Oct; 299():122836. PubMed ID: 37196550
[TBL] [Abstract][Full Text] [Related]
2. Determination of Gemcitabine and Sorafenib in Spiked Human Plasma Using Multivariate Model Update Chemometric Methods.
Sharkawi MMZ; Mohamed NR; El-Saadi MT; Amin NH
J AOAC Int; 2023 Nov; 106(6):1666-1672. PubMed ID: 37233147
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
[TBL] [Abstract][Full Text] [Related]
4. Ecofriendly LC-MS/MS and TLC-densitometric methods for simultaneous quantitative assay and monitoring of BEGEV regimen,
Sharkawi MMZ; Mohamed NR; El-Saadi MT; Amin NH
Anal Methods; 2023 Feb; 15(8):1016-1027. PubMed ID: 36727667
[TBL] [Abstract][Full Text] [Related]
5. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Zanni M; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Ricci F; Carlo-Stella C
Blood Adv; 2020 Jan; 4(1):136-140. PubMed ID: 31935284
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
[TBL] [Abstract][Full Text] [Related]
7. BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience.
Stefoni V; Argnani L; Carella M; Casadei B; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Coppola PE; Zinzani PL
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1043-1047. PubMed ID: 35239000
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM; Blum KA
Cancer; 2020 Mar; 126(6):1235-1242. PubMed ID: 31821549
[TBL] [Abstract][Full Text] [Related]
9. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Zhang YC; Wang JN; Ma SY; Cai J; Su N; Huang HQ; Li ZM; Xia ZJ; Huang H; Liu PP; Xia Y; Cai QQ
Br J Haematol; 2022 Jan; 196(1):127-135. PubMed ID: 34618912
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
11. Multivariate Model Update Chemometric Methods for Determination of Prednisolone and Esomeprazole in Spiked Human Plasma: A Comparative Study.
Farid NF; Magdy MA; Anwar BH; Abdelhamid NS
J AOAC Int; 2022 Feb; 105(1):317-322. PubMed ID: 34478551
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy Analysis of Bendamustine-Based Combination Regimen in Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma].
Guo YT; Li F; Dong WM; Lin Y; Xie XB; Ling Y; Yan F; Hua XY; He B; Gu WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1766-1771. PubMed ID: 36476901
[TBL] [Abstract][Full Text] [Related]
13. High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
Swoboda R; Giebel S; Knopińska-Posłuszny W; Chmielowska E; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Kulikowski W; Taszner M; Mendrek W; Najda J; Czerw T; Olszewska-Szopa M; Czyż A; Giza A; Spychałowicz W; Subocz E; Szwedyk P; Krzywon A; Wilk A; Zaucha JM
Ann Hematol; 2021 Jul; 100(7):1755-1767. PubMed ID: 33625572
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation.
Ozkaynak MF; Jayabose S
Pediatr Hematol Oncol; 2004 Mar; 21(2):107-13. PubMed ID: 15160509
[TBL] [Abstract][Full Text] [Related]
17. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
19. Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids.
Abdelhameed AS; Attwa MW; Attia MI; Alanazi AM; Alruqi OS; AlRabiah H
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jan; 264():120336. PubMed ID: 34481256
[TBL] [Abstract][Full Text] [Related]
20. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Naqi N; Ahmad S; Shah I; Khattak J
J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
